Stamaril

Stamaril is a live, attenuated yellow fever vaccine derived from the 17D-204 strain, used for active immunization against yellow fever. This vaccine helps protect travelers and residents in endemic regions. Store and administer as directed by healthcare professionals.

Stamaril is used to prevent yellow fever, a mosquito-borne viral infection common in tropical regions of Africa and South America. It is recommended for travelers visiting high-risk areas and for laboratory workers handling yellow fever virus. The vaccine stimulates the immune system to produce antibodies against the virus. It is not suitable for everyone and should be administered under medical supervision.

After vaccination, the body’s immune system responds by producing antibodies to fight yellow fever. Some individuals may experience mild effects such as a low-grade fever, headache, or muscle pain. These effects are generally temporary and resolve within a few days. The vaccine does not cause yellow fever infection as the virus is weakened.

Stamaril should be handled and administered by a healthcare professional. Individuals with weakened immune systems, severe egg allergies, or certain medical conditions may need to avoid or delay vaccination. Inform your healthcare provider of any allergies or medications before receiving the vaccine. Keep the vaccine refrigerated until use.

Stamaril may interact with immunosuppressive therapies, including corticosteroids or chemotherapy, potentially reducing its effectiveness. Avoid other live vaccines for at least 4 weeks before or after receiving Stamaril unless approved by a healthcare provider. Discuss any recent or planned medical treatments with your doctor.